Home > Drugs A – Z > Glipizide (By mouth)

Glipizide (By mouth)

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Glipizide is used to treat high blood sugar levels caused by a type of diabetes mellitus (sugar diabetes) called type 2 diabetes. In type 2 diabetes, your body does not work properly to store excess sugar and the sugar remains in your bloodstream. Chronic high blood sugar can lead to serious health problems in the future. Proper diet is the first step in managing type 2 diabetes, but often… Read more
Brand names include
Glucotrol, Glucotrol XL
Drug classes About this
Hypoglycemic
Combinations including this drug

What works? Research summarized

Evidence reviews

Effects and patient compliance of sustained-release versus immediate-release glipizides in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

This review concluded that sustained-release glipizide appeared to achieve similar glucose control with decreased insulin secretion, fewer hypoglycaemic episodes and higher patient compliance than immediate-release glipizide but the findings were inconclusive due to low study quality, short follow-up and lack of patient important outcomes. These conclusions reflect the evidence presented and are likely to be reliable.

Second- and Third-Line Pharmacotherapy for Type 2 Diabetes — Update of CADTH 2010 Reviews — Project Protocol [Internet]

In August 2010, the Canadian Agency for Drugs and Technologies in Health (CADTH) published an Optimal Therapy Report which assessed the clinical and cost-effectiveness of second-line therapies for patients with type 2 diabetes inadequately controlled on metformin. The results from the CADTH review indicated that there were no apparent differences in efficacy across drug classes, and that sulfonylureas were the most cost-effective treatment option. Based on these analyses, the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) Expert Review Committee (CERC) recommended that most patients requiring a second treatment after metformin should be prescribed a sulfonylurea. CADTH followed this report with a Therapeutic Review which examined the evidence for third-line treatment options for adults with type 2 diabetes inadequately controlled on metformin and a sulfonylurea. The results demonstrated that insulins (basal, biphasic, bolus), dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, and thiazolidinediones (TZDs) all produced statistically significant reductions in hemoglobin A1C in combination with metformin and a sulphonylurea. Meglitinides and alpha-glucosidase inhibitors, however, did not. The addition of insulin neutral protamine Hagedorn (NPH) to metformin plus a sulfonylurea was associated with the most favourable cost-effectiveness estimates. CADTH’s Therapeutic Review Panel (TRP) recommended that, for most adults with type 2 diabetes inadequately controlled on metformin and a sulfonylurea, insulin NPH should be added as the third-line agent. Long-acting insulin analogues at prices similar to insulin NPH were also considered an option for patients inadequately controlled on metformin and a sulfonylurea.

Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet]

To compare the effectiveness and adverse event profiles of amylin agonists, DPP-4 inhibitors, incretin mimetics, TZDs, and certain combination products for people with type 2 diabetes and for people with type 1 diabetes for pramlintide only.

See all (55)

Summaries for consumers

Sitagliptin (Januvia or Xelevia) for type 2 diabetes: Comparing the combination sitagliptin/metformin with glipizide/metformin

The Institute for Quality and Efficiency in Health Care (IQWiG, Germany) last looked into how sitagliptin (trade name: Januvia or Xelevia) compares with standard treatments in 2016. The results of one study comparing the combination sitagliptin/metformin with glipizide/metformin were available for analysis. The drug glipizide has not been approved for use in Germany. The following results apply only to patients for whom the aim of drug therapy is to lower blood sugar levels as much as possible.

Comparing newer drugs for diabetes, including combination drugs

How do newer drugs for diabetes compare in lowering blood sugar levels?

Medicines for Type 2 Diabetes: A Review of the Research for Adults

This summary covers the research on the benefits and possible side effects of medicines to lower or control your blood sugar. It will help you talk with your doctor or other health care professional to decide which medicines are best for you.

See all (10)

PubMed Health Blog...

read all...